サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1623932

非感染性黄斑浮腫治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Non-infectious Macular Edema Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 323 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
非感染性黄斑浮腫治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年01月03日
発行: Persistence Market Research
ページ情報: 英文 323 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の非感染性黄斑浮腫治療の市場規模は、2025年に114億米ドルになるとみられ、2025年～2032年の予測期間に8.10%のCAGRで拡大し、2032年には197億米ドルに達すると予測されています。

世界の非感染性黄斑浮腫治療市場は、抗VEGF薬、副腎皮質ステロイド薬、免疫抑制薬、生物学的製剤、その他を含む幅広い治療オプションで構成されています。市場の拡大は、主に糖尿病に関連する合併症の増加と、地域全体における眼関連疾患に対する意識の高まりによってもたらされます。硝子体内インプラントの承認など、ドラッグ製剤やデリバリーメカニズムの進歩により、治療成績や患者のアドヒアランスが大幅に向上しています。

世界の非感染性黄斑浮腫治療市場の成長は、複数の要因によって牽引されています。糖尿病黄斑浮腫（DME）を含む糖尿病およびその合併症の有病率の上昇により、効果的な治療ソリューションに対する需要が高まっています。眼関連疾患の早期発見・治療に対する意識の高まりが、市場をさらに押し上げています。低用量高効能コルチコステロイドインプラントや硝子体内薬などの先進的治療法の発売と採用は、特に北米と欧州における治療プロトコルに革命をもたらしました。さらに、副腎皮質ステロイドとの併用、あるいは単独治療としての免疫抑制剤の利用拡大により、患者が利用できる治療選択肢の幅が広がっています。これらの進歩により、より良い疾患管理と生活の質の向上が保証されています。

非感染性黄斑浮腫治療市場は大きな成長の可能性を秘めています。次世代の硝子体内インプラントや標的製剤の開発などの技術進歩により、治療効果と患者のコンプライアンスが向上しています。メトトレキサートやミコフェノール酸モフェチルなどの免疫調節薬の採用が増加しており、全身性ステロイドの限界に対処することで新たな機会がもたらされています。新興国における啓発キャンペーンや検診プログラムの拡大は、早期診断と治療の需要を促進すると予想されます。さらに、アジア太平洋や中東・アフリカのような未開拓の潜在力は、市場参入企業がプレゼンスを拡大し、アンメット・メディカル・ニーズに対応するための有利な機会を提供します。

当レポートでは、世界の非感染性黄斑浮腫治療市場について調査し、薬剤タイプ別、投与経路別、適応症別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 非感染性黄斑浮腫治療市場概要

第4章 非感染性黄斑浮腫治療の市場機会分析

  • マクロ経済要因
  • 機会分析

第5章 市場背景

  • 市場力学
  • 償還の情勢
  • 規制シナリオ

第6章 北米の非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）

第7章 ラテンアメリカの非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）

第8章 欧州の非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）

第9章 アジア太平洋の非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）

第10章 日本の非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）

第11章 中東・アフリカの非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）

第12章 予測要因：関連性と影響および予測の前提条件

第13章 市場構造分析

第14章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 企業の詳細
    • Allergan, Plc.
    • Pfizer, Inc.
    • Novartis AG
    • F. Hoffman - La Roche Ltd.
    • AbbVie Inc.
    • Bayer AG
    • Valeant Pharmaceuticals Inc.
    • Alimera Sciences Inc.
    • Clearside Biomedical, Inc.
    • Amgen, Inc.

第15章 世界の非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）、地域別

第16章 世界の非感染性黄斑浮腫治療分析（2020年～2024年）および予測（2025年～2032年）、薬剤タイプ別

第17章 世界の非感染性黄斑浮腫治療分析（2020年～2024年）および予測（2025年～2032年）、投与経路別

第18章 非感染性黄斑浮腫治療の世界市場分析（2020年～2024年）および予測（2025年～2032年）、適応症別

第19章 世界の非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）、流通チャネル別

第20章 世界の非感染性黄斑浮腫治療市場分析（2020年～2024年）および予測（2025年～2032年）

第21章 調査手法

目次
Product Code: PMRREP22984

Persistence Market Research has recently released a comprehensive report on the global Non-Infectious Macular Edema Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Non-Infectious Macular Edema Treatment Market Size (2025E): US$11.4 Bn
  • Projected Market Value (2032F): US$19.7 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.10%

Non-Infectious Macular Edema Treatment Market - Report Scope:

The global non-infectious macular edema treatment market comprises a wide range of therapeutic options, including Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics, and others. The market's expansion is primarily driven by increasing diabetes-related complications and growing awareness of eye-related diseases across regions. Advances in drug formulations and delivery mechanisms, such as the approval of Intravitreal Implants, have significantly enhanced treatment outcomes and patient adherence. The report also provides insights into regional dynamics, treatment adoption trends, and competitive strategies.

Market Drivers:

The growth of the global non-infectious macular edema treatment market is driven by multiple factors. The rising prevalence of diabetes and its complications, including diabetic macular edema (DME), has led to an increased demand for effective therapeutic solutions. Growing awareness about early detection and treatment of eye-related diseases has further boosted the market. The launch and adoption of advanced therapies, such as low-dose high-efficacy corticosteroid implants and intravitreal medications, have revolutionized treatment protocols, particularly in North America and Europe. Moreover, the growing utilization of immunosuppressants, either in combination with corticosteroids or as standalone treatments, has broadened the scope of treatment options available for patients. These advancements ensure better disease management and improved quality of life.

Market Restraints:

The market faces certain challenges that may hinder its growth. High costs associated with treatments like Anti-VEGF and corticosteroid injections, combined with the necessity of repeated administration, have raised affordability and adherence concerns among patients. The availability of alternative treatment options and off-label drug use has also affected the market's potential, as patients often seek cost-effective and less invasive solutions. Furthermore, the launch of biosimilars for some blockbuster anti-VEGF agents is expected to decrease market opportunities for branded drugs. Counterfeit products and the lack of standardized treatment protocols in some regions also act as significant barriers to market growth.

Market Opportunities:

The non-infectious macular edema treatment market offers significant growth potential. Technological advancements, such as the development of next-generation Intravitreal Implants and targeted formulations, have enhanced treatment efficacy and patient compliance. Increasing adoption of immunomodulators, such as methotrexate and mycophenolate mofetil, presents new opportunities by addressing the limitations of systemic steroids. Expanding awareness campaigns and screening programs in emerging economies are expected to drive demand for early diagnosis and treatment. Additionally, the untapped potential in regions like Asia-Pacific and the Middle East & Africa provides lucrative opportunities for market players to expand their presence and address unmet medical needs.

Key Questions Answered in the Report:

  • What factors are driving the global growth of the non-infectious macular edema treatment market?
  • How are advancements in Intravitreal Implants and immunosuppressant therapies influencing market dynamics?
  • Which drug types are expected to witness the highest adoption rates during the forecast period?
  • What are the challenges faced by the market, and how can they be mitigated?
  • Which regions offer the most promising growth opportunities for market players?

Competitive Intelligence and Business Strategy:

Leading companies in the global non-infectious macular edema treatment market are focusing on expanding their product portfolios and geographical reach. Key players are investing in research and development to bring innovative solutions to market, such as next-generation corticosteroids and advanced biologics. Strategic collaborations with academic institutions and regulatory agencies are facilitating faster approval and adoption of new therapies. Companies are also leveraging digital platforms and telemedicine to enhance patient engagement and streamline treatment administration.

Key Companies Profiled:

  • Allergan, Plc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffman - La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Valeant Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Clearside Biomedical, Inc.
  • Others.

Non-infectious Macular Edema Treatment Market Segmentation:

By Drug Type:

  • Anti-VEGF
  • Corticosteroids
  • Immunosuppressants
  • Biologics
  • Others

By Indication:

  • Non-Infectious Uveitic Macular Edema
  • Diabetic Macular Edema
  • Retinal Vein Occlusion with Macular Edema

By Route of Administration:

  • Oral
  • Parenteral
  • Topical

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Japan
  • Middle East & Africa (MEA)
  • Asia-Pacific (APAC)

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy
  • 2.3. Primary Research - Verbatim
  • 2.4. Global Non-infectious Macular Edema Treatment Market - Trade Overview

3. Non-infectious Macular Edema Treatment Market Overview

  • 3.1. Patient's Journey Through Non-infectious Uveitic Macular Edema Treatment Process
  • 3.2. Management Flowchart For Non-infectious Uveitis Macular Edema Treatment
  • 3.3. Patient's Journey Through Diabetic Macular Edema Treatment Process
  • 3.4. Management Flowchart For Diabetic Macular Edema Treatment
  • 3.5. Patient's Journey Through Retinal Vein Occlusion Macular Edema Treatment Process
  • 3.6. Management Flowchart For Retinal Vein Occlusion Macular Edema Treatment
  • 3.7. Epidemiology
    • 3.7.1. Non-infectious Uveitis Macular Edema
    • 3.7.2. Diabetic Macular Edema
    • 3.7.3. Retinal Vain Occlusion with Macular Edema
  • 3.8. Impact Analysis
    • 3.8.1. Anti-VEGF Therapies
    • 3.8.2. Corticosteroids
    • 3.8.3. Immunosuppressant
    • 3.8.4. Biologics
  • 3.9. U.S. Key Regulations - Macular Edema
  • 3.10. Macular Edema Drugs: U.S. FDA Regulatory Scenario
  • 3.11. Global Macular Edema Market Pipeline Analysis
  • 3.12. Treatment Summary
  • 3.13. Macular Edema Treatment Market - Supply Chain Analysis
  • 3.14. Economic and Clinical Value Measures in Pricing of Macular Edema Treatment

4. Non-infectious Macular Edema Treatment Market Opportunity Analysis

  • 4.1. Macro-Economic Factors
  • 4.2. Opportunity Analysis

5. Market Background

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
    • 5.1.2. Restraints
    • 5.1.3. Trends
  • 5.2. Reimbursement Landscape
  • 5.3. Regulatory Scenario

6. North America Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

  • 6.1. Introduction
  • 6.2. Historical Market Size (US$ Bn ) Trend Analysis By Country, 2020 - 2024
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Market Size (US$ Bn ) Forecast By Country, 2025 - 2032
  • 6.4. Historical Market Size (US$ Bn ) Trend Analysis By Drug Type, 2020 - 2024
    • 6.4.1. Anti-VEGF
    • 6.4.2. Corticosteroids
    • 6.4.3. Immunosuppressant
    • 6.4.4. Biologics
    • 6.4.5. Others
  • 6.5. Market Size (US$ Bn ) Forecast By Drug Type, 2025 - 2032
  • 6.6. Historical Market Size (US$ Bn ) Trend Analysis By Route of Administration, 2020 - 2024
    • 6.6.1. Oral
    • 6.6.2. Parenteral
    • 6.6.3. topical
  • 6.7. Market Size (US$ Bn ) Forecast By Route of Administration, 2025 - 2032
  • 6.8. Historical Market Size (US$ Bn ) Trend Analysis By Indication, 2020 - 2024
    • 6.8.1. Non-infectious Uveitic Macular Edema
    • 6.8.2. Diabetic Macular Edema
    • 6.8.3. Retinal Vein Occlusion with Macular Edema
  • 6.9. Market Size (US$ Bn ) Forecast By Indication, 2025 - 2032
  • 6.10. Historical Market Size (US$ Bn ) Trend Analysis By Distribution Channel, 2020 - 2024
    • 6.10.1. Hospital Pharmacies
    • 6.10.2. Retail Pharmacies
    • 6.10.3. Online Pharmacies
  • 6.11. Market Size (US$ Bn ) Forecast By Distribution Channel, 2025 - 2032
  • 6.12. Drivers and Restraints: Impact Analysis
  • 6.13. Market Attractiveness Analysis
    • 6.13.1. By Country
    • 6.13.2. By Drug Type
    • 6.13.3. By Route of Administration
    • 6.13.4. By Indication
    • 6.13.5. By Distribution Channel
  • 6.14. Drivers and Restraints - Impact Analysis

7. Latin America Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

  • 7.1. Introduction
  • 7.2. Historical Market Size (US$ Bn ) Trend Analysis By Country, 2020 - 2024
    • 7.2.1. Brazil
    • 7.2.2. Mexico
    • 7.2.3. Rest of Latin America
  • 7.3. Market Size (US$ Bn ) Forecast By Country, 2025 - 2032
  • 7.4. Historical Market Size (US$ Bn ) Trend Analysis By Drug Type, 2020 - 2024
    • 7.4.1. Anti-VEGF
    • 7.4.2. Corticosteroids
    • 7.4.3. Immunosuppressant
    • 7.4.4. Biologics
    • 7.4.5. Others
  • 7.5. Market Size (US$ Bn ) Forecast By Drug Type, 2025 - 2032
  • 7.6. Historical Market Size (US$ Bn ) Trend Analysis By Route of Administration, 2020 - 2024
    • 7.6.1. Oral
    • 7.6.2. Parenteral
    • 7.6.3. topical
  • 7.7. Market Size (US$ Bn ) Forecast By Route of Administration, 2025 - 2032
  • 7.8. Historical Market Size (US$ Bn ) Trend Analysis By Indication, 2020 - 2024
    • 7.8.1. Non-infectious Uveitic Macular Edema
    • 7.8.2. Diabetic Macular Edema
    • 7.8.3. Retinal Vein Occlusion with Macular Edema
  • 7.9. Market Size (US$ Bn ) Forecast By Indication, 2025 - 2032
  • 7.10. Historical Market Size (US$ Bn ) Trend Analysis By Distribution Channel, 2020 - 2024
    • 7.10.1. Hospital Pharmacies
    • 7.10.2. Retail Pharmacies
    • 7.10.3. Online Pharmacies
  • 7.11. Market Size (US$ Bn ) Forecast By Distribution Channel, 2025 - 2032
  • 7.12. Drivers and Restraints: Impact Analysis
  • 7.13. Market Attractiveness Analysis
    • 7.13.1. By Country
    • 7.13.2. By Drug Type
    • 7.13.3. By Route of Administration
    • 7.13.4. By Indication
    • 7.13.5. By Distribution Channel
  • 7.14. Drivers and Restraints - Impact Analysis

8. Europe Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

  • 8.1. Introduction
  • 8.2. Historical Market Size (US$ Bn ) Trend Analysis By Country, 2020 - 2024
    • 8.2.1. Germany
    • 8.2.2. U.K.
    • 8.2.3. France
    • 8.2.4. Italy
    • 8.2.5. Spain
    • 8.2.6. Russia
    • 8.2.7. Rest of Europe
  • 8.3. Market Size (US$ Bn ) Forecast By Country, 2025 - 2032
  • 8.4. Historical Market Size (US$ Bn ) Trend Analysis By Drug Type, 2020 - 2024
    • 8.4.1. Anti-VEGF
    • 8.4.2. Corticosteroids
    • 8.4.3. Immunosuppressant
    • 8.4.4. Biologics
    • 8.4.5. Others
  • 8.5. Market Size (US$ Bn ) Forecast By Drug Type, 2025 - 2032
  • 8.6. Historical Market Size (US$ Bn ) Trend Analysis By Route of Administration, 2020 - 2024
    • 8.6.1. Oral
    • 8.6.2. Parenteral
    • 8.6.3. topical
  • 8.7. Market Size (US$ Bn ) Forecast By Route of Administration, 2025 - 2032
  • 8.8. Historical Market Size (US$ Bn ) Trend Analysis By Indication, 2020 - 2024
    • 8.8.1. Non-infectious Uveitic Macular Edema
    • 8.8.2. Diabetic Macular Edema
    • 8.8.3. Retinal Vein Occlusion with Macular Edema
  • 8.9. Market Size (US$ Bn ) Forecast By Indication, 2025 - 2032
  • 8.10. Historical Market Size (US$ Bn ) Trend Analysis By Distribution Channel, 2020 - 2024
    • 8.10.1. Hospital Pharmacies
    • 8.10.2. Retail Pharmacies
    • 8.10.3. Online Pharmacies
  • 8.11. Market Size (US$ Bn ) Forecast By Distribution Channel, 2025 - 2032
  • 8.12. Drivers and Restraints: Impact Analysis
  • 8.13. Market Attractiveness Analysis
    • 8.13.1. By Country
    • 8.13.2. By Drug Type
    • 8.13.3. By Route of Administration
    • 8.13.4. By Indication
    • 8.13.5. By Distribution Channel
  • 8.14. Drivers and Restraints - Impact Analysis

9. APAC Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

  • 9.1. Introduction
  • 9.2. Historical Market Size (US$ Bn ) Trend Analysis By Country, 2020 - 2024
    • 9.2.1. China
    • 9.2.2. Australia
    • 9.2.3. India
    • 9.2.4. Rest of APAC
  • 9.3. Market Size (US$ Bn ) Forecast By Country, 2025 - 2032
  • 9.4. Historical Market Size (US$ Bn ) Trend Analysis By Drug Type, 2020 - 2024
    • 9.4.1. Anti-VEGF
    • 9.4.2. Corticosteroids
    • 9.4.3. Immunosuppressant
    • 9.4.4. Biologics
    • 9.4.5. Others
  • 9.5. Market Size (US$ Bn ) Forecast By Drug Type, 2025 - 2032
  • 9.6. Historical Market Size (US$ Bn ) Trend Analysis By Route of Administration, 2020 - 2024
    • 9.6.1. Oral
    • 9.6.2. Parenteral
    • 9.6.3. topical
  • 9.7. Market Size (US$ Bn ) Forecast By Route of Administration, 2025 - 2032
  • 9.8. Historical Market Size (US$ Bn ) Trend Analysis By Indication, 2020 - 2024
    • 9.8.1. Non-infectious Uveitic Macular Edema
    • 9.8.2. Diabetic Macular Edema
    • 9.8.3. Retinal Vein Occlusion with Macular Edema
  • 9.9. Market Size (US$ Bn ) Forecast By Indication, 2025 - 2032
  • 9.10. Historical Market Size (US$ Bn ) Trend Analysis By Distribution Channel, 2020 - 2024
    • 9.10.1. Hospital Pharmacies
    • 9.10.2. Retail Pharmacies
    • 9.10.3. Online Pharmacies
  • 9.11. Market Size (US$ Bn ) Forecast By Distribution Channel, 2025 - 2032
  • 9.12. Drivers and Restraints: Impact Analysis
  • 9.13. Market Attractiveness Analysis
    • 9.13.1. By Country
    • 9.13.2. By Drug Type
    • 9.13.3. By Route of Administration
    • 9.13.4. By Indication
    • 9.13.5. By Distribution Channel
  • 9.14. Drivers and Restraints - Impact Analysis

10. Japan Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Bn ) Trend Analysis By Drug Type, 2020 - 2024
    • 10.2.1. Anti-VEGF
    • 10.2.2. Corticosteroids
    • 10.2.3. Immunosuppressant
    • 10.2.4. Biologics
    • 10.2.5. Others
  • 10.3. Market Size (US$ Bn ) Forecast By Drug Type, 2025 - 2032
  • 10.4. Historical Market Size (US$ Bn ) Trend Analysis By Route of Administration, 2020 - 2024
    • 10.4.1. Oral
    • 10.4.2. Parenteral
    • 10.4.3. topical
  • 10.5. Market Size (US$ Bn ) Forecast By Route of Administration, 2025 - 2032
  • 10.6. Historical Market Size (US$ Bn ) Trend Analysis By Indication, 2020 - 2024
    • 10.6.1. Non-infectious Uveitic Macular Edema
    • 10.6.2. Diabetic Macular Edema
    • 10.6.3. Retinal Vein Occlusion with Macular Edema
  • 10.7. Market Size (US$ Bn ) Forecast By Indication, 2025 - 2032
  • 10.8. Historical Market Size (US$ Bn ) Trend Analysis By Distribution Channel, 2020 - 2024
    • 10.8.1. Hospital Pharmacies
    • 10.8.2. Retail Pharmacies
    • 10.8.3. Online Pharmacies
  • 10.9. Market Size (US$ Bn ) Forecast By Distribution Channel, 2025 - 2032
  • 10.10. Drivers and Restraints: Impact Analysis
  • 10.11. Market Attractiveness Analysis
    • 10.11.1. By Drug Type
    • 10.11.2. By Route of Administration
    • 10.11.3. By Indication
    • 10.11.4. By Distribution Channel
  • 10.12. Drivers and Restraints - Impact Analysis

11. MEA Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Bn ) Trend Analysis By Country, 2020 - 2024
    • 11.2.1. GCC Countries
    • 11.2.2. South Africa
    • 11.2.3. Rest of MEA
  • 11.3. Market Size (US$ Bn ) Forecast By Country, 2025 - 2032
  • 11.4. Historical Market Size (US$ Bn ) Trend Analysis By Drug Type, 2020 - 2024
    • 11.4.1. Anti-VEGF
    • 11.4.2. Corticosteroids
    • 11.4.3. Immunosuppressant
    • 11.4.4. Biologics
    • 11.4.5. Others
  • 11.5. Market Size (US$ Bn ) Forecast By Drug Type, 2025 - 2032
  • 11.6. Historical Market Size (US$ Bn ) Trend Analysis By Route of Administration, 2020 - 2024
    • 11.6.1. Oral
    • 11.6.2. Parenteral
    • 11.6.3. topical
  • 11.7. Market Size (US$ Bn ) Forecast By Route of Administration, 2025 - 2032
  • 11.8. Historical Market Size (US$ Bn ) Trend Analysis By Indication, 2020 - 2024
    • 11.8.1. Non-infectious Uveitic Macular Edema
    • 11.8.2. Diabetic Macular Edema
    • 11.8.3. Retinal Vein Occlusion with Macular Edema
  • 11.9. Market Size (US$ Bn ) Forecast By Indication, 2025 - 2032
  • 11.10. Historical Market Size (US$ Bn ) Trend Analysis By Distribution Channel, 2020 - 2024
    • 11.10.1. Hospital Pharmacies
    • 11.10.2. Retail Pharmacies
    • 11.10.3. Online Pharmacies
  • 11.11. Market Size (US$ Bn ) Forecast By Distribution Channel, 2025 - 2032
  • 11.12. Drivers and Restraints: Impact Analysis
  • 11.13. Market Attractiveness Analysis
    • 11.13.1. By Country
    • 11.13.2. By Drug Type
    • 11.13.3. By Route of Administration
    • 11.13.4. By Indication
    • 11.13.5. By Distribution Channel
  • 11.14. Drivers and Restraints - Impact Analysis

12. Forecast Factors: Relevance and Impact and Forecast Assumptions

13. Market Structure Analysis

  • 13.1. Market Structure by Tier of Companies

14. Competition Analysis

  • 14.1. Competition Dashboard
  • 14.2. Competition Benchmarking
  • 14.3. Company Deep Dive
    • 14.3.1. Allergan, Plc.
      • 14.3.1.1. Overview
      • 14.3.1.2. Product and Infection Type Portfolio
      • 14.3.1.3. Production Footprint
      • 14.3.1.4. Sales Footprint
      • 14.3.1.5. Channel Footprint
      • 14.3.1.6. Strategy
        • 14.3.1.6.1. Marketing Strategy
        • 14.3.1.6.2. Product Strategy
        • 14.3.1.6.3. Channel Strategy
    • 14.3.2. Pfizer, Inc.
      • 14.3.2.1. Overview
      • 14.3.2.2. Product and Infection Type Portfolio
      • 14.3.2.3. Production Footprint
      • 14.3.2.4. Sales Footprint
      • 14.3.2.5. Channel Footprint
      • 14.3.2.6. Strategy
        • 14.3.2.6.1. Marketing Strategy
        • 14.3.2.6.2. Product Strategy
        • 14.3.2.6.3. Channel Strategy
    • 14.3.3. Novartis AG
      • 14.3.3.1. Overview
      • 14.3.3.2. Product and Infection Type Portfolio
      • 14.3.3.3. Production Footprint
      • 14.3.3.4. Sales Footprint
      • 14.3.3.5. Channel Footprint
      • 14.3.3.6. Strategy
        • 14.3.3.6.1. Marketing Strategy
        • 14.3.3.6.2. Product Strategy
        • 14.3.3.6.3. Channel Strategy
    • 14.3.4. F. Hoffman - La Roche Ltd.
      • 14.3.4.1. Overview
      • 14.3.4.2. Product and Infection Type Portfolio
      • 14.3.4.3. Production Footprint
      • 14.3.4.4. Sales Footprint
      • 14.3.4.5. Channel Footprint
      • 14.3.4.6. Strategy
        • 14.3.4.6.1. Marketing Strategy
        • 14.3.4.6.2. Product Strategy
        • 14.3.4.6.3. Channel Strategy
    • 14.3.5. AbbVie Inc.
      • 14.3.5.1. Overview
      • 14.3.5.2. Product and Infection Type Portfolio
      • 14.3.5.3. Production Footprint
      • 14.3.5.4. Sales Footprint
      • 14.3.5.5. Channel Footprint
      • 14.3.5.6. Strategy
        • 14.3.5.6.1. Marketing Strategy
        • 14.3.5.6.2. Product Strategy
        • 14.3.5.6.3. Channel Strategy
    • 14.3.6. Bayer AG
      • 14.3.6.1. Overview
      • 14.3.6.2. Product and Infection Type Portfolio
      • 14.3.6.3. Production Footprint
      • 14.3.6.4. Sales Footprint
      • 14.3.6.5. Channel Footprint
      • 14.3.6.6. Strategy
        • 14.3.6.6.1. Marketing Strategy
        • 14.3.6.6.2. Product Strategy
        • 14.3.6.6.3. Channel Strategy
    • 14.3.7. Valeant Pharmaceuticals Inc.
      • 14.3.7.1. Overview
      • 14.3.7.2. Product and Infection Type Portfolio
      • 14.3.7.3. Production Footprint
      • 14.3.7.4. Sales Footprint
      • 14.3.7.5. Channel Footprint
      • 14.3.7.6. Strategy
        • 14.3.7.6.1. Marketing Strategy
        • 14.3.7.6.2. Product Strategy
        • 14.3.7.6.3. Channel Strategy
    • 14.3.8. Alimera Sciences Inc.
      • 14.3.8.1. Overview
      • 14.3.8.2. Product and Infection Type Portfolio
      • 14.3.8.3. Production Footprint
      • 14.3.8.4. Sales Footprint
      • 14.3.8.5. Channel Footprint
      • 14.3.8.6. Strategy
        • 14.3.8.6.1. Marketing Strategy
        • 14.3.8.6.2. Product Strategy
        • 14.3.8.6.3. Channel Strategy
    • 14.3.9. Clearside Biomedical, Inc.
      • 14.3.9.1. Overview
      • 14.3.9.2. Product and Infection Type Portfolio
      • 14.3.9.3. Production Footprint
      • 14.3.9.4. Sales Footprint
      • 14.3.9.5. Channel Footprint
      • 14.3.9.6. Strategy
        • 14.3.9.6.1. Marketing Strategy
        • 14.3.9.6.2. Product Strategy
        • 14.3.9.6.3. Channel Strategy
    • 14.3.10. Amgen, Inc.
      • 14.3.10.1. Overview
      • 14.3.10.2. Product and Infection Type Portfolio
      • 14.3.10.3. Production Footprint
      • 14.3.10.4. Sales Footprint
      • 14.3.10.5. Channel Footprint
      • 14.3.10.6. Strategy
        • 14.3.10.6.1. Marketing Strategy
        • 14.3.10.6.2. Product Strategy
        • 14.3.10.6.3. Channel Strategy

15. Global Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032, By Region

  • 15.1. Introduction/Key Findings
  • 15.2. Historical Market Size (US$ Bn ) Trend Analysis By Region, 2020 - 2024
  • 15.3. Market Size (US$ Bn ) Forecast By Region, 2025 - 2032
    • 15.3.1. North America
    • 15.3.2. Latin America
    • 15.3.3. Europe
    • 15.3.4. APAC
    • 15.3.5. Japan
    • 15.3.6. Middle East and Africa (MEA)
  • 15.4. Market Attractiveness Analysis By Region

16. Global Non-infectious Macular Edema Treatment Analysis 2020 - 2024 and Forecast 2025 - 2032, By Drug Type

  • 16.1. Introduction/Key Findings
  • 16.2. Historical Market Size (US$ Bn ) Trend Analysis By Drug Type, 2020 - 2024
    • 16.2.1. Anti-VEGF
    • 16.2.2. Corticosteroids
    • 16.2.3. Immunosuppressant
    • 16.2.4. Biologics
    • 16.2.5. Others
  • 16.3. Market Size (US$ Bn ) and Volume Forecast By Drug Type, 2025 - 2032
  • 16.4. Market Attractiveness Analysis By Drug Type

17. Global Non-infectious Macular Edema Treatment Analysis 2020 - 2024 and Forecast 2025 - 2032, By Route of Administration

  • 17.1. Introduction/Key Findings
  • 17.2. Historical Market Size (US$ Bn ) Trend Analysis By Route of Administration, 2020 - 2024
    • 17.2.1. Oral
    • 17.2.2. Parenteral
    • 17.2.3. Topical
  • 17.3. Market Size (US$ Bn ) and Volume Forecast By Route of Administration, 2025 - 2032
  • 17.4. Market Attractiveness Analysis By Route of Administration

18. Global Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032, By Indication

  • 18.1. Introduction/Key Findings
  • 18.2. Historical Market Size (US$ Bn ) Trend Analysis By Indication, 2020 - 2024
    • 18.2.1. Non-infectious Uveitic Macular Edema
    • 18.2.2. Diabetic Macular Edema
    • 18.2.3. Retinal Vein Occlusion with Macular Edema
  • 18.3. Market Size (US$ Bn ) Forecast By Indication, 2025 - 2032
  • 18.4. Market Attractiveness Analysis By Indication

19. Global Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032, By Distribution Channel

  • 19.1. Introduction/Key Findings
  • 19.2. Historical Market Size (US$ Bn ) Trend Analysis By Distribution Channel, 2020 - 2024
    • 19.2.1. Hospital Pharmacies
    • 19.2.2. Retail Pharmacies
    • 19.2.3. Online Pharmacies
  • 19.3. Market Size (US$ Bn ) Forecast By Distribution Channel, 2025 - 2032
  • 19.4. Market Attractiveness Analysis By Distribution Channel

20. Global Non-infectious Macular Edema Treatment Market Analysis 2020 - 2024 and Forecast 2025 - 2032

  • 20.1. Market Value Share Analysis By All Segment
  • 20.2. Y-o-Y Growth Analysis By All Segment
  • 20.3. Absolute $ Opportunity

21. Research Methodology